|
|
| | MeOSuc-Ala-Phe-Lys-AMC TFA Basic information |
| Product Name: | MeOSuc-Ala-Phe-Lys-AMC TFA | | Synonyms: | MeOSuc-Ala-Phe-Lys-AMC;MeOSuc-AFK-AMC;methyl 4-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoate;L-Lysinamide,N-(4-methoxy-1,4-dioxobutyl)-L-alanyl-L-phenylalanyl-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)-,mono(trifluoroacetate);MeOSuc-Ala-Phe-Lys-AMC TFA | | CAS: | 201853-92-1 | | MF: | C33H41N5O8.C2HF3O2 | | MW: | 749.73 | | EINECS: | | | Product Categories: | | | Mol File: | 201853-92-1.mol |  |
| | MeOSuc-Ala-Phe-Lys-AMC TFA Chemical Properties |
| storage temp. | -15°C | | Sequence | {MeOSuc}-Ala-Phe-Lys-{AMC} |
| | MeOSuc-Ala-Phe-Lys-AMC TFA Usage And Synthesis |
| Uses | MeOSuc-Ala-Phe-Lys-AMC TFA is a peptide substrate of plasmin[1]. | | References | [1] Dall jl, et, al. Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors. Cardiovasc Res. 2010 Jan 1;85(1):184-93. DOI:10.1093/cvr/cvp253 |
| | MeOSuc-Ala-Phe-Lys-AMC TFA Preparation Products And Raw materials |
|